|
1
|
Ridge CA, McErlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: Cancer incidence and mortality worldwide: IARC CancerBase.
GLOBOCAN 2012 v10. 11:2012.
|
|
3
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the human
development index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Center for Chronic Disease
Prevention and Health Promotion (US) Office on Smoking and Health,
. The Health Consequences of Smoking-50 Years of Progress: A Report
of the Surgeon General. Centers for Disease Control and Prevention
(US). (Atlanta, GA). 2014.
|
|
5
|
Fucito LM, Czabafy S, Hendricks PS, Kotsen
C, Richardson D and Toll BA; Association for the Treatment of
Tobacco Use and Dependence/Society for Research on Nicotine and
Tobacco Synergy Committee, : Pairing smoking-cessation services
with lung cancer screening: A clinical guideline from the
association for the treatment of tobacco use and dependence and the
society for research on nicotine and tobacco. Cancer.
122:1150–1159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nana-Sinkam SP and Powell CA: Molecular
biology of lung cancer: Diagnosis and management of lung cancer,
3rd ed: American college of chest physicians evidence-based
clinical practice guidelines. Chest. 143 (5 Suppl):e30S–e39S. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krebs AM, Mitschke J, Lasierra Losada M,
Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D,
Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key
factor for cell plasticity and promotes metastasis in pancreatic
cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nieto MA: Context-specific roles of EMT
programmes in cancer cell dissemination. Nat Cell Biol. 19:416–418.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH,
Majeski HE, Chen AC, Sah RL, Taylor SS, Engler AJ and Yang J:
Matrix stiffness drives epithelial-mesenchymal transition and
tumour metastasis through a TWIST1-G3BP2 mechanotransduction
pathway. Nat Cell Biol. 17:678–688. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsai JH, Donaher JL, Murphy DA, Chau S and
Yang J: Spatiotemporal regulation of epithelial-mesenchymal
transition is essential for squamous cell carcinoma metastasis.
Cancer Cell. 22:725–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Shi X, Peng Y, Wu M, Zhang P, Xie
R, Wu Y, Yan Q, Liu S and Wang J: HIF-1α promotes
epithelial-mesenchymal transition and metastasis through direct
regulation of ZEB1 in colorectal cancer. PLoS One. 10:e01296032015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chaffer CL, Marjanovic ND, Lee T, Bell G,
Kleer CG, Reinhardt F, D'Alessio AC, Young RA and Weinberg RA:
Poised chromatin at the ZEB1 promoter enables breast cancer cell
plasticity and enhances tumorigenicity. Cell. 154:61–74. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop-a motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cong N, Du P, Zhang A, Shen F, Su J, Pu P,
Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a
promotes EMT and tumor growth through the wnt/β-catenin pathway by
targeting the E-cadherin repressors ZEB1/ZEB2 in gastric
adenocarcinoma. Oncol Rep. 29:1579–1587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y,
Zhang J, Yuan J, Wang M, Chen D, Sun Y, et al: ATM-mediated
stabilization of ZEB1 promotes DNA damage response and
radioresistance through CHK1. Nat Cell Biol. 16:864–875. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng H and Kang Y: Multilayer control of
the EMT master regulators. Oncogene. 33:1755–1763. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tamagawa S, Beder LB, Hotomi M, Gunduz M,
Yata K, Grenman R and Yamanaka N: Role of miR-200c/miR-141 in the
regulation of epithelial-mesenchymal transition and migration in
head and neck squamous cell carcinoma. Int J Mol Med. 33:879–886.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiong M, Jiang L, Zhou Y, Qiu W, Fang L,
Tan R, Wen P and Yang J: The miR-200 family regulates
TGF-β1-induced renal tubular epithelial to mesenchymal transition
through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J
Physiol Renal Physiol. 302:F369–F379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y, Yin J, Abou-Kheir W, Hynes PG,
Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, et
al: MiR-1 and miR-200 inhibit EMT via Slug-dependent and
tumorigenesis via Slug-independent mechanisms. Oncogene.
32:296–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feng X, Wang Z, Fillmore R and Xi Y:
MiR-200, a new star miRNA in human cancer. Cancer Lett.
344:166–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen A, Lin W, Chen Y, Liu L, Chen H,
Zhuang Q, Lin J, Sferra TJ and Peng J: Pien Tze Huang inhibits
metastasis of human colorectal carcinoma cells via modulation of
TGF-β1/ZEb/mir-200 signaling network. Int J Oncol. 46:685–690.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren J, Chen Y, Song H, Chen L and Wang R:
Inhibition of ZEB1 reverses EMT and chemoresistance in
docetaxel-resistant human lung adenocarcinoma cell line. J Cell
Biochem. 114:1395–1403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou Z, Zhang P, Hu X, Kim J, Yao F, Xiao
Z, Zeng L, Chang L, Sun Y and Ma L: USP51 promotes deubiquitination
and stabilization of ZEB1. Am J Cancer Res. 7:2020–2031.
2017.PubMed/NCBI
|
|
29
|
Wang Z, Zhang H, Liu J, Cheruiyot A, Lee
JH, Ordog T, Lou Z, You Z and Zhang Z: USP51 deubiquitylates
H2AK13, 15ub and regulates DNA damage response. Genes Dev.
30:946–959. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Atanassov BS, Mohan RD, Lan X, Kuang X, Lu
Y, Lin K, McIvor E, Li W, Zhang Y, Florens L, et al: ATXN7L3 and
ENY2 coordinate activity of multiple H2B deubiquitinases important
for cellular proliferation and tumor growth. Mol Cell. 62:558–571.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hong J, Kang B, Kim A, Hwang S, Ahn J, Lee
S, Kim J, Park JH and Cheon DS: Development of a highly sensitive
real-time one step RT-PCR combined complementary locked primer
technology and conjugated minor groove binder probe. Virol J.
8:3302011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Zhang G, Zhang H, Zhang F, Zhou B,
Ning F, Wang HS, Cai SH and Du J: Acquisition of
epithelial-mesenchymal transition phenotype and cancer stem
cell-like properties in cisplatin-resistant lung cancer cells
through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol.
723:156–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hong W, Cai P, Xu C, Cao D, Yu W, Zhao Z,
Huang M and Jin J: Inhibition of glucose-6-phosphate dehydrogenase
reverses cisplatin resistance in lung cancer cells via the redox
system. Front Pharmacol. 9:432018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao X, Yu S, Li S, Wu J, Ma R, Cao H, Zhu
Y and Feng J: Exosomes: Decreased sensitivity of lung cancer A549
cells to cisplatin. PLoS One. 9:e895342014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sandhu SK, Schelman WR, Wilding G, Moreno
V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A,
et al: The poly (ADP-ribose) polymerase inhibitor niraparib
(MK4827) in BRCA mutation carriers and patients with sporadic
cancer: A phase 1 dose-escalation trial. Lancet Oncol. 14:882–892.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brentnall M, Rodriguez-Menocal L, De
Guevara RL, Cepero E and Boise LH: Caspase-9, caspase-3 and
caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell
Biol. 14:322013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ning J, Zhang J, Liu W, Lang Y, Xue Y and
Xu S: Overexpression of ubiquitin-specific protease 22 predicts
poor survival in patients with early-stage non-small cell lung
cancer. Eur J Histochem. 56:e462012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F,
Bao G, Kong H, Ge C, Zhang F, et al: MiRNA-200c inhibits invasion
and metastasis of human non-small cell lung cancer by directly
targeting ubiquitin specific peptidase 25. Mol Cancer. 13:1662014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu X, Liu J, Shen C, Ding L, Zhong F,
Ouyang Y, Wang Y and He S: The role of ubiquitin-specific protease
14 (USP 14) in cell adhesion-mediated drug resistance (CAM-DR) of
multiple myeloma cells. Eur J Haematol. 98:4–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang D, Qian G, Wang J, Wang T, Zhang L,
Yang P and Lin F: Visfatin is involved in the cisplatin resistance
of osteosarcoma cells via upregulation of Snail and Zeb1. Cancer
Biol Ther. 20:999–1006. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zou J, Liu L, Wang Q, Yin F, Yang Z, Zhang
W and Li L: Downregulation of miR-429 contributes to the
development of drug resistance in epithelial ovarian cancer by
targeting ZEB1. Am J Transl Res. 9:1357–1368. 2017.PubMed/NCBI
|
|
43
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP,
Lee S, Park SK, Han MK, Lee SY, Ramkumar KM, et al: SIRT1
activation by resveratrol ameliorates cisplatin-induced renal
injury through deacetylation of p53. Am J Physiol Renal Physiol.
301:F427–F435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen A, Wong CS, Liu MC, House CM, Sceneay
J, Bowtell DD, Thompson EW and Möller A: The ubiquitin ligase Siah
is a novel regulator of Zeb1 in breast cancer. Oncotarget.
6:862–873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu M, Zhu C, Zhao X, Chen C, Zhang H, Yuan
H, Deng R, Dou J, Wang Y, Huang J, et al: Atypical ubiquitin E3
ligase complex Skp1-Pam-Fbxo45 controls the core
epithelial-to-mesenchymal transition-inducing transcription
factors. Oncotarget. 6:979–984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu Y, Yue C, Li J, Wu J, Wang S, Sun D,
Guo Y, Lin Z, Zhang D and Wang R: Enhancement of cisplatin
cytotoxicity by Retigeric acid B involves blocking DNA repair and
activating DR5 in prostate cancer cells. Oncol Lett. 15:2871–2880.
2018.PubMed/NCBI
|
|
48
|
Lin KW, Huang AM, Lin CC, Chang CC, Hsu
WC, Hour TC, Pu YS and Lin CN: Anti-cancer effects of ursane
triterpenoid as a single agent and in combination with cisplatin in
bladder cancer. Eur J Pharmacol. 740:742–751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chauhan D, Tian Z, Nicholson B, Kumar KG,
Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov
MP, et al: A small molecule inhibitor of ubiquitin-specific
protease-7 induces apoptosis in multiple myeloma cells and
overcomes bortezomib resistance. Cancer Cell. 22:345–358. 2012.
View Article : Google Scholar : PubMed/NCBI
|
